Clinical trials: Spine Disease
Arthritis, Psoriatic, Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists
The purpose of this study is to evaluate the safety and effectiveness of etanercept under usual care settings in patients with PsA treated by rheumatologists.
- Conditions
- Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous
- Trial name
- NCT00293722
- Testing
- Etanercept
- Where
- Germany
- Volunteers
- 1,308 people
- Sponsor
- Pfizer
Early Lumbar Disc Degeneration
A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration
Study to show the safety, tolerability and preliminary effectiveness of Intradiscal rhGDF-5 in subjects with early lumbar disc degeneration.
- Trial name
- NCT01158924
- Testing
- Intradiscal rhGDF-5
- Where
- 3 sites in Australia
- Volunteers
- 40 people
- Sponsor
- DePuy Spine
Arthritis, Psoriatic
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066/ABBV-066/risankizumab in adult patients with psoriatic arthritis in order to select doses for further…
- Trial name
- NCT02719171
- Testing
- risankizumab
- Volunteers
- 185 people
- Sponsor
- AbbVie
Axial Spondyloarthrithis, Ankylosing Spondylitis
Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo
Patients receive study drug for one year (Part A). If, after the initial run-in phase, a sustained remission is reached they will be randomly split into one of three dose groups for another year (Part B).
- Trial name
- C-OPTIMISE (NCT02505542)
- Testing
- Certolizumab Pegol
- Where
- 108 sites in United States, Belgium and 12 more
- Volunteers
- 736 people
- Sponsor
- UCB BIOSCIENCES GmbH
Lumbar Spinal Stenosis
MiDAS III (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study
This is a multi-center, prospective, observational clinical study to compare patient outcomes following treatment with either the mild® procedure or epidural steroid injection in patients with moderate to severe lumbar spinal…
- Trial name
- MiDAS III (NCT01315145)
- Testing
- Percutaneous Lumbar Decompression, Epidural Steroid Injection
- Where
- 27 sites in United States
- Volunteers
- 138 people
- Sponsor
- Vertos Medical, Inc.
Psoriatic Arthritis
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.
- Trial name
- NCT01925768
- Testing
- Apremilast 30 mg
- Where
- 71 sites in United States, Australia and 8 more
- Volunteers
- 219 people
- Sponsor
- Amgen
Ankylosing Spondylitis
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
The purpose of this study is to demonstrate the impact of secukinumab on the progression of structural damage in the spine, as measured by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) in patients with Ankylosing…
- Trial name
- SURPASS (NCT03259074)
- Testing
- GP2017 (adalimumab biosimilar), AIN457 150 mg
- Where
- 171 sites in United States, Argentina and 27 more
- Volunteers
- 859 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.
- Trial name
- OPAL BEYOND (NCT01882439)
- Testing
- Tofacitinib
- Where
- 125 sites in United States, Australia and 12 more
- Volunteers
- 395 people
- Sponsor
- Pfizer
Degeneration of Lumbar Intervertebral Disc
OptiMesh® for Lumbar Interbody Fusion Trial (OLIF)
The purpose of this study was to collect data to demonstrate the safety and effectiveness of the OptiMesh 1500S to contain and reinforce bone graft materials in patients with Degenerative Disc Disease (DDD) whose condition…
- Trial name
- OLIF (NCT00764491)
- Testing
- Structural Allograft Spacer, OptiMesh 1500S
- Where
- 11 sites in United States
- Volunteers
- 156 people
- Sponsor
- Spineology, Inc
Spondyloarthritis
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biological disease-modifying anti-rheumatic drugs (bDMARDs)-naive participants with radiographic axial…
- Trial name
- COAST-V (NCT02696785)
- Testing
- Ixekizumab, Adalimumab
- Where
- 28 sites in United States, Czechia and 5 more
- Volunteers
- 341 people
- Sponsor
- Eli Lilly and Company
Ankylosing Spondylitis
Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis
Study of the efficacy and safety of adalimumab compared with placebo in adult Chinese participants with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal…
- Trial name
- NCT01114880
- Testing
- adalimumab
- Where
- 9 sites in China
- Volunteers
- 344 people
- Sponsor
- Abbott
Ankylosing Spondylitis
Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA
The purpose of this global study was to demonstrate the efficacy, safety, and tolerability of an intravenous (i.v.) regimen of secukinumab compared to placebo in participants with active ankylosing spondylitis (AS) or…
- Trial name
- NCT04156620
- Testing
- Secukinumab
- Where
- 102 sites in United States, Belgium and 16 more
- Volunteers
- 527 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab
- Trial name
- NCT03552276
- Testing
- SUNPG18_07 I (Tildrakizumab 200 mg), SUNPG18_07 II (Tildrakizumab 100 mg)
- Where
- 66 sites in United States, Argentina and 6 more
- Volunteers
- 281 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Axial Spondyloarthritis
A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)
This study is a non-interventional, longitudinal and non-confirmatory study to compare an active supervised training (AST) with standard of care (SOC) physiotherapy in patients with axial spondyloarthritis and stable response to…
- Trial name
- Treat & Train (NCT03258814)
- Testing
- Active Supervised Training (AST), Standard of Care (SOC) Physiotherapy
- Where
- 6 sites in Germany
- Volunteers
- 17 people
- Sponsor
- AbbVie
Lumbar Spinal Stenosis
MiDAS I (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study
This is a multi-center, prospective, clinical study to assess the clinical application and outcomes of MILD® Interlaminar Decompression in patients with symptomatic lumbar spinal stenosis.
- Trial name
- MiDAS I (NCT00956631)
- Testing
- Interlaminar Decompression
- Where
- 13 sites in United States
- Volunteers
- 78 people
- Sponsor
- Vertos Medical, Inc.
Psoriatic Arthritis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs.
- Trial name
- NCT04908202
- Testing
- Deucravacitinib
- Where
- 183 sites in United States, Argentina and 19 more
- Volunteers
- 670 people
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE 1 (NCT03675308)
- Testing
- Risankizumab
- Where
- 256 sites in United States, Argentina and 37 more
- Volunteers
- 964 people
- Sponsor
- AbbVie
Low Bone Mass, Low Bone Mineral Density
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
The purpose of this study is to assess how effective and safe denosumab is in a population of males with low bone mass at risk of fracture.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Males With Osteoporosis, Osteopenia
- Trial name
- NCT00980174
- Testing
- 60 mg denosumab
- Volunteers
- 242 people
- Sponsor
- Amgen
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
- Trial name
- BE VIVID (NCT03370133)
- Testing
- Bimekizumab, Ustekinumab
- Where
- 105 sites in United States, Australia and 9 more
- Volunteers
- 567 people
- Sponsor
- UCB Biopharma SRL
Spondylitis, Ankylosing
Extension in AS: Sustainability of Benefits, Safety and Tolerability
This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as…
- Trial name
- MEASURE 1 ext (NCT01863732)
- Testing
- Secukinumab
- Where
- 56 sites in United States, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Novartis Pharmaceuticals